Heartflow, Inc.
As of Oct 22, 2026, Heartflow is in Stage 2, the uptrend phase, now in week 10 (since Aug 19, 2026). It closed at $55.43, at its 52-week high and above its 200-day average, which is rising.
HeartFlow, Inc., a medical technology company, provides non-invasive solutions for diagnosing and managing coronary artery diseases the United States and worldwide. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 16 in Health Information Services · #1 of 272 in Health Care
Is HTFL early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
HTFL among Health Information Services6th of 41 by relative strength
All 41 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | AMWL | Stage 2 · wk 25 | 97 | +7.4% |
| 2 | HNGE | Stage 2 · wk 20 | 96 | +19.1% |
| 3 | BTSG | Stage 3 · wk 8 | 94 | +9.1% |
| 4 | NRC | Stage 3 · wk 4 | 93 | −0.1% |
| 5 | SOPH | Stage 2 · wk 24 | 91 | −12.7% |
| 6 | HTFL | Stage 2 · wk 10 | 87 | +17.0% |
| 7 | HSTM | Stage 2 · wk 17 | 77 | +20.3% |
| 8 | OMCL | Stage 4 · wk 10 | 70 | +12.5% |
Heartflow: quick answers
What stage is Heartflow in?
As of Oct 22, 2026, Heartflow (HTFL) is in Stage 2, the uptrend phase. It entered Stage 2 on Aug 19, 2026 and is in week 10. What the four stages mean
Is Heartflow in an uptrend?
Yes. Heartflow is in a Stage 2 uptrend. It trades 66.2% above its 200-day average, which is rising.
How far is Heartflow from its 52-week high?
Heartflow closed at $55.43 on Oct 22, 2026, at its 52-week high. Its 52-week low is $20.49.
How has Heartflow performed over the past year?
As of Oct 22, 2026, Heartflow is up 51.3% over the past year and up 91.3% so far in 2026.
Which sector and industry is Heartflow in?
Heartflow is in the Health Information Services industry, part of the Health Care sector.
About this companyHealth Care· Health Information Services
HeartFlow, Inc., a medical technology company, provides non-invasive solutions for diagnosing and managing coronary artery diseases the United States and worldwide. Its HeartFlow Platform uses AI and computational fluid dynamics to creates a personalized 3D model of a patient's heart from a single coronary computed tomography angiography, a specialized type of scan that provides detailed images of the heart's arteries. The company provides Heartflow RoadMap Analysis that offers an intuitive anatomic visualization of the coronary arteries; Heartflow FFRCT Analysis, which calculates blood flow and pinpoints clinically; and Heartflow Plaque Analysis that provides a comprehensive assessment of coronary plaque, enabling optimized medical treatment strategies. Its platform provides insights on blood flow, stenosis, and plaque volume and composition by overcoming the limitations of traditional non-invasive imaging tests. HeartFlow, Inc. was formerly known as Cardiovascular Simulation, Inc. and changed its name to HeartFlow, Inc. in May 2009. The company was incorporated in 2007 and is headquartered in San Francisco, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.